Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00346866
NCT00346866CompletedPhase 2

Anecortave Acetate Versus Placebo in AMD Patients Following PDT

Alcon Research2 sites in 1 country136 target enrollmentStarted: May 2000Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
136
Locations
2
Primary Endpoint
Mean change from the baseline in logMAR visual acuity score at Month 6
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study was to evaluate the efficacy of anecortave acetate for depot suspension (30 mg and 15 mg) plus PDT versus PDT alone with respect to maintenance of visual acuity in patients with wet AMD.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
50 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •AMD disease

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Mean change from the baseline in logMAR visual acuity score at Month 6

Secondary Outcomes

  • % patients who maintained vision, number of months of angiographic evidence of needing PDT re-treatment, and mean lesion sizes for the total choroidal neovascularization (CNV) and the classic component to the total CNV.

Investigators

Sponsor Class
Industry

Study Sites (2)

Loading locations...

Similar Trials

Completed
Phase 3
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMDMaculopathy, Age-RelatedMacular Degeneration
NCT00058994Alcon Research
Terminated
Phase 3
Anecortave Acetate Risk Reduction Trial (AART)AMD
NCT00332657Alcon Research36
Completed
Phase 3
Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)Maculopathy, Age-RelatedAge-Related MaculopathiesAge-Related MaculopathyMaculopathies, Age-RelatedMacular Degeneration
NCT00051129Alcon Research291
Completed
Phase 2
Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) ElevationEye Diseases
NCT00315640Alcon Research70
Terminated
Phase 3
Anecortave Acetate Risk-Reduction Trial (AART)AMD
NCT00333216Alcon Research24